LY 2886721

• Catalog No.: S2156
• CAS Number: 1262036-50-9
• M. F.: C18H16F2N4O2S
• M. W.: 390.4070464
• Storage: -20°C

SYNONYMS

• IUPAC name: N-{3-[(4aS,7aS)-2-amino-4H,4aH,5H,7H,7aH-furo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide
• IUPAC Traditional name: N-{3-[(4aS,7aS)-2-amino-4H,4aH,5H,7H-furo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide
• Synonyms: LY2886721

DATABASE IDS

• CAS Number: 1262036-50-9

PROPERTIES

• Salt Data: Free Base
• Storage Condition: -20°C

DETAILS

Description (English)

Research Area

• Description: Neurological Disease

Biological Activity

• Description: LY2886721 is an BACE inhibitor used for the treatment of Alzheimer’s Disease.
• Targets: BACE; γ-secretase
• In Vitro: LY2886721 is an oral, small molecule of ?-site amyloid protein cleaving enzyme (BACE) inhibitor with the potential to inhibit the synthesis of ?-amyloid and thereby to slow the clinical progression of AD. ^[1] LY2886721 can also targetγ-secretase to nhibit the synthesis of ?-amyloid. ^[2]
• Clinical Trials: LY2886721 is currently in a Phase II clinical trial in patients with Mild Cognitive Impairment.

References

• References: [1] Adru studies, 2012
• References: [2] Townsend M, et al. J Alzheimers Dis, 2011, 24 Suppl 2, 43-52.

REFERENCES

• Adru studies, 2012
• Townsend M, et al. J Alzheimers Dis, 2011, 24 Suppl 2, 43-52.